Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DU2Q0R
|
|||
| Drug Name |
TBI-166
|
|||
| Synonyms |
TBI-166; UNII-TY9R7N6MS5; TY9R7N6MS5; TBI166; 1353734-12-9; TBI 166; pyrifazimine; SCHEMBL805734; CHEMBL2177933; GTPL12961; GUSGYHIQYWRCQO-NXEFEZKASA-N; GUSGYHIQYWRCQO-UHFFFAOYSA-N; EX-A7135; SB18777; MS-30513; HY-148564; CS-0636566; (3E)-3-(4-methoxycyclohexyl)imino-N-(2-methoxy-3-pyridyl)-5-[4-(trifluoromethoxy)phenyl]phenazin-2-amine; 2-PHENAZINAMINE, 3,5-DIHYDRO-3-((4-METHOXYCYCLOHEXYL)IMINO)-N-(2-METHOXY-3-PYRIDINYL)-5-(4-(TRIFLUOROMETHOXY)PHENYL)-; 3-((4-Methoxycyclohexyl)imino)-N-(2-methoxypyridin-3-yl)-5-(4-(trifluoromethoxy)phenyl)-3,5-dihydrophenazin-2-amine; 3-(4-methoxycyclohexyl)imino-N-(2-methoxypyridin-3-yl)-5-[4-(trifluoromethoxy)phenyl]phenazin-2-amine
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Pulmonary tuberculosis [ICD-11: 1B10.Z] | Phase 2 | [1] | |
| Company |
TB
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C32H30F3N5O3
|
|||
| Canonical SMILES |
COC1CCC(CC1)N=C2C=C3C(=NC4=CC=CC=C4N3C5=CC=C(C=C5)OC(F)(F)F)C=C2NC6=C(N=CC=C6)OC
|
|||
| InChI |
InChI=1S/C32H30F3N5O3/c1-41-22-13-9-20(10-14-22)37-27-19-30-28(18-26(27)39-25-7-5-17-36-31(25)42-2)38-24-6-3-4-8-29(24)40(30)21-11-15-23(16-12-21)43-32(33,34)35/h3-8,11-12,15-20,22,39H,9-10,13-14H2,1-2H3
|
|||
| InChIKey |
GUSGYHIQYWRCQO-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04670120) Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With Pyrifazimine (TBI-166). U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.